Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: A meta-analysis

Medicine (United States)

Volumn 94, Issue 4, 2015, Pages

  Zhang, Jing Tao ^a   Chen, Ke Ping ^a   Zhang, Shu ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; DEATH; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPLICATION; HEART ATRIUM FIBRILLATION; ORAL DRUG ADMINISTRATION; PULMONARY EMBOLISM; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PULMONARY EMBOLISM; STROKE; WARFARIN;

EID: 84938097572     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000409     Document Type: Article

References (44)

1. Santulli G. Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. J Cardiovasc Dis. 2013; 1:1-2.
2. Chugh SS, Havmoeller R, Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129:837-847.
3. Lubitz SA, Bauer KA, Benjamin E.J., et al. Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar. J Am Geriatr Soc. 2013; 61:1798-1803.
4. Ball J, Carrington MJ, McMurray J.J., et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013; 167:1807-1824.
5. January CT, Wann LS, Alpert J.S., et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014; 130:2071-2104.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983-988.
7. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998; 158:1513-1521.
8. Soff GA. A new generation of oral direct anticoagulants. Arterioscler Thromb Vasc Biol. 2012; 32:569-574.
9. Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004; 4:CD000187.
10. Segal JB, McNamara RL, Miller M.R., et al. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med. 2000; 15:56-67.
11. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. Chichester, West Sussex, UK: The Cochrane Collaboration; 2011.
12. ACTIVE Writing Group of the ACTIVE Investigators Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet. 2006; 367: 1903-1912.
13. Brandes A, Overgaard M, Plauborg L., et al. Guideline adherence of antithrombotic treatment initiated by general practitioners in patients with nonvalvular atrial fibrillation: a Danish survey. Clin Cardiol. 2013; 36:427-432.
14. Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsa-licylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVER-ROES) trial. Stroke. 2012; 43:3291-3297.
15. Flaker GC, Gruber M, Connolly S.J., et al., SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006; 152:967-973.
16. Formiga F, Ferrer A, Mimbrera D., et al., Grupo de Estudio Octabaix. High rate of anticoagulation therapy in oldest old subjects with atrial fibrillation: the Octabaix study. J Am Med Dir Assoc. 2012; 13:8-10.
17. Ghaswalla PK, Harpe SE, Slattum PW. Warfarin use in nursing home residents: results from the 2004 national nursing home survey. Am J Geriatr PharmacoTher. 2012; 10:25-36.e2.
18. Granger CB, Alexander JH, McMurray J.J., et al., ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981-992.
19. Hart RG, Pearce LA, Asinger R.W., et al. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6:2599-2604.
20. Kirchhof P, Ammentorp B, Darius H., et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014; 16:6-14.
21. Morocutti C, Amabile G, Fattapposta F., et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke. 1997; 28:1015-1021.
22. Bertomeu-González V, Cordero A, Mazón P, et al., Investigators of the CARDIOTENS2 study. Anticoagulation prescription in atrial fibrillation. Expert Opin PharmacoTher. 2011; 12:1473-1479.
23. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007; 6:115-124.
24. Mohr JP, Thompson JL, Lazar R.M., et al., Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001; 345:1444-1451.
25. Colli A, Mestres CA, Castella M, et al. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis. 2007; 16:667-671.
26. Lip GY, Rasmussen LH, Olsson S.B., et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb Res. 2011; 127:91-99.
27. Lavitola Pde L, Sampaio RO, Oliveira W.A., et al. Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation. Arq Bras Cardiol. 2010; 95:749-755.
28. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370:493-503.
29. Rash A, Downes T, Portner R., et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007; 36:151-156.
30. Hellemons BS, Langenberg M, Lodder J., et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999; 319:958-964.
31. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994; 343:687-691.
32. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med. 1996; 156:409-416.
33. Petersen P, Boysen G, Godtfredsen J., et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of throm-boembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989; 1:175-179.
34. Hu DY, Zhang HP, Sun Y.H., et al. The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin [article in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2006; 34:295-298.
35. Wakili R, Voigt N, Kääb S, et al. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011; 121:2955-2968.
36. Xie W, Santulli G, Guo X., et al. Imaging atrial arrhythmic intracellular calcium in intact heart. J Mol Cell Cardiol. 2013; 64:120-123.
37. Santulli G, D'ascia SL, D'ascia C. Development of atrial fibrillation in recipients of cardiac resynchronization therapy: the role of atrial reverse remodelling. Can J Cardiol. 2012; 28:245.e17.
38. Santulli G, Iaccarino G, De Luca N, et al. Atrial fibrillation and microRNAs. Front Physiol. 2014; 5:15.
39. Lanni F, Santulli G, Izzo R., et al. The Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. J Hypertens. 2007; 25:551-556.
40. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplate-let therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007; 3:CD006186.
41. Andersen LV, Vestergaard P, Deichgraeber P., et al. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart. 2008; 94:1607-1613.
42. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007; 147:590-592.
43. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993; 342:1255-1262.
44. Connolly SJ, Pogue J, Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118:2029-2037.